What question did this study set out to answer?

The aim is to report the occurrence of acute hepatitis B in an individual following a switch to CAB+RPV LA.

January 18, 2026Sexually Transmitted Infections0 citations

Acute hepatitis B following a switch to long-acting cabotegravir plus rilpivirine in an individual with a history of hepatitis B vaccination

VMValentina MorenaAlessandro Manzoni Hospital NGNicole GemignaniAlessandro Manzoni Hospital SESimoncini Elena

Key Points

The aim is to report the occurrence of acute hepatitis B in an individual following a switch to CAB+RPV LA.
Detailed case analysis of an individual with history of hepatitis B vaccination
Treatment switch to CAB+RPV LA
Monitoring for hepatitis B infection post-treatment switch
Observation of acute hepatitis B after the treatment switch
Individual had a prior vaccination history for hepatitis B

Abstract

Injectable long-acting cabotegravir plus rilpivirine (CAB+RPV LA) is an effective treatment option for people living with HIV. Unlike regimens containing tenofovir with lamivudine (3TC) or emtricitabine (FTC), it lacks therapeutic activity against the hepatitis B virus, and hepatitis B vaccination is recommended for non-immune individuals. We present a case of acute hepatitis B after switching to CAB+RPV LA in a previously vaccinated individual.

AI से पूछें

Bookmark

View Full Paper